RP.V - RepliCel Life Sciences Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.2600
-0.0400 (-13.33%)
At close: 1:53PM EDT
Stock chart is not supported by your current browser
Previous Close0.3000
Open0.2750
Bid0.2600 x 0
Ask0.2700 x 0
Day's Range0.2600 - 0.2800
52 Week Range0.2600 - 0.5300
Volume48,049
Avg. Volume18,910
Market Cap7.159M
Beta (3Y Monthly)0.50
PE Ratio (TTM)N/A
EPS (TTM)-0.1350
Earnings DateNov 27, 2015 - Nov 30, 2015
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.64
  • PR Newswire

    RepliCel's Partner, YOFOTO (China) Health, Unveils its Inaugural Cell Therapy Manufacturing Facility in China

    In a recent update to the RepliCel Board of Directors, the YOFOTO team reported that construction of its 4,700 sq metre facility dedicated to cell therapy manufacturing is now complete being commissioned for active production with capacity for clinical research manufacturing, material handling, purified water processing, research and development labs, QC/QA testing, cryopreservation storage, clinical biopsy/treatment space, and an exhibition hall.

  • PR Newswire

    RepliCel Life Sciences Retains Dermatology Sales and Marketing Executive to Guide the Global Commercial Strategy for its Automated Dermal Injector

    VANCOUVER, Aug. 29, 2019 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announces it has retained the services of Damien King, an aesthetic dermatology product specialist and former executive in several top-tier companies, to help build out the global commercial strategy for the Company's automated dermal injector, RCI-02, and related consumables (the "RCI-02 Product Line").  RepliCel's RCI-02 Product Line is expected to market launch next year in Europe and Hong Kong after receiving CE marketing approval in the first half of 2020. Mr. King has more than 20 years of in-depth experience in the sales and marketing of pharmaceutical, biologic, and medical device products for some of the world's largest life science companies.

  • Reuters

    BRIEF-RepliCel Secures New Patents For Its Regenerative Medicine Technologies

    April 16 (Reuters) - Replicel Life Sciences Inc: * REPLICEL SECURES SEVERAL NEW PATENTS FOR ITS REGENERATIVE MEDICINE TECHNOLOGIES * REPLICEL LIFE SCIENCES-RECENTLY RECEIVED NOTIFICATIONS OF MANY PATENTS ...

  • PR Newswire

    RepliCel Secures Several New Patents for its Regenerative Medicine Technologies

    VANCOUVER, April 16, 2019 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has recently received notifications of several patents issued, allowed, and granted to the Company from Europe, China, Hong Kong, Japan, the United States and South Africa.

  • PR Newswire

    RepliCel's Licensee Building Momentum in China with Facility and Team

    VANCOUVER, March 26, 2019 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that its Licensee, YOFOTO (China) Health Co. ("YOFOTO"), headquartered in Ningbo, China, is rapidly building momentum on its licensed programs for Greater China, since closing the transaction with RepliCel in October last year.

  • RepliCel Reignites its First-in-Japan Strategy
    CNW Group

    RepliCel Reignites its First-in-Japan Strategy

    VANCOUVER , March 19, 2019 /CNW/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce the resumption of their First-in- Japan strategy. The Company, working with industry leaders, CJ PARTNERS, have initiated a program in Japan to realize its goal of launching its cell therapy products in Japan sooner than would be possible anywhere else in the world.

  • RepliCel CEO Provides 2019 Shareholder Update
    CNW Group

    RepliCel CEO Provides 2019 Shareholder Update

    VANCOUVER , March 5, 2019 /CNW/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to provide an update to shareholders from its President and CEO, Mr. R. Lee Buckler . First, a quick recap of our Annual General Meeting held December 14, 2018 at which the shareholders elected a new slate of directors to RepliCel's Board - some re-elected, some new. The Board now has higher shareholder representation as well as a duly-elected nominee of our new investor/partner in Greater China .

  • RepliCel Life Sciences Appoints Head of Clinical and Regulatory Affairs
    CNW Group

    RepliCel Life Sciences Appoints Head of Clinical and Regulatory Affairs

    VANCOUVER , Nov. 06, 2018 /CNW/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announces the appointment of European Clinical and Regulatory Affairs expert, Dr. Petra Goessens-Rueck , as Head of Clinical and Regulatory Affairs. Dr. Petra Goessens-Rueck has been a valuable consultant to RepliCel since its inception assisting with research, development, clinical and regulatory strategy in addition to managing regulatory submissions and most aspects of the Company's clinical trials.

  • PR Newswire

    RepliCel Announces Federal Grant Funding for Collaboration with the University of Victoria, Canada

    VANCOUVER and VICTORIA, BC, Oct. 18, 2018 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company") is pleased to announce it has signed a collaborative research project agreement with the University of Victoria ("UVic") in Victoria, B.C., Canada. The project will be co-funded through a grant from the National Science and Engineering Research Council of Canada ("NSERC") under the NSERC Collaborative Research and Development ("CRD") program.

  • RepliCel Life Sciences Appoints New Chief Financial Officer
    CNW Group

    RepliCel Life Sciences Appoints New Chief Financial Officer

    VANCOUVER , Oct. 17, 2018 /CNW/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announces that its board of directors has appointed Simon Ma as the Chief Financial Officer of the Company.  Mr. Ma is the current Director of Finance and succeeds Tom Kordyback who has resigned as the Chief Financial Officer to enjoy his full-time retirement from professional service. Mr. Ma is a Chartered Professional Accountant and has extensive experience with private and public companies. Simon Ma has been a sole public practitioner since 1997 and is practicing under the name of Simon S. Ma Corporation.

  • RepliCel CEO Provides Updated Outlook
    CNW Group

    RepliCel CEO Provides Updated Outlook

    VANCOUVER , Oct. 15, 2018 /CNW/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to provide an update to shareholders from its President and CEO, Mr. R. Lee Buckler . Now that we have closed our deal with YOFOTO, I am very pleased to provide this updated outlook. In January, I outlined our progress over the past 24 months and included our goals for 2018 which, I said, would be focused on "...leveraging partnerships to drive the Company towards maturation." Last week, we announced we had closed an investment with YOFOTO ( China ) Health Industry Co. Ltd ("YOFOTO"), which is now a significant shareholder and business partner.

  • RepliCel Life Sciences Completes Financing with YOFOTO (China) Health
    CNW Group

    RepliCel Life Sciences Completes Financing with YOFOTO (China) Health

    VANCOUVER and NINGBO, China , Oct, 11, 2018 /CNW/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today it has completed the anticipated strategic investment (the "Transaction") with YOFOTO ( China ) Health Industry Co. Ltd. ("YOFOTO").

  • RepliCel Life Sciences and YOFOTO (China) Health Obtain All Approvals Needed to Complete Investment
    CNW Group

    RepliCel Life Sciences and YOFOTO (China) Health Obtain All Approvals Needed to Complete Investment

    VANCOUVER and NINGBO, China , Sept. 24, 2018 /CNW/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has received, from the TSX Venture Exchange, the conditional approval required to complete the investment which is part of a previously announced collaboration agreement (the "Transaction") focused on commercialization of select RepliCel products in Greater China .